Adjustments for Non-Cash Items (USD, thousands)

Stock-Based Compensation (USD, thousands)

Changes in Working Capital (USD, thousands)

Capital Expenditures (CapEx) (USD, thousands)

Proceeds from / Repayments of Debt (USD, thousands)

Share Repurchases (USD, thousands)

Dividend Payments (USD, thousands)

Net Change in Cash (USD, thousands)

17d4af7f252e5e8317d18d4e36a373ac3a4e5682b38b8f2db8f96437fd7ae91b

Medical Device

- Product Sales

- Royalties & License Fees - Coatings

- License Fees - SurVeil DCB

- Research, Development, and Other

In Vitro Diagnostics

Total Revenue

afddb59f9094a52499112fa8683c49695463c35bdf40b540f4879734fe4142b2

Total Revenue (USD, thousands)

Cost of Goods Sold (COGS) (USD, thousands)

Selling, General, and Administrative Expenses (SG&A) (USD, thousands)

Research and Development (R&D) (USD, thousands)

Depreciation and Amortization (D&A) (USD, thousands)

Interest Expense (USD, thousands)

Operating Income (EBIT) (USD, thousands)

Net Income (USD, thousands)

Earnings Per Share (EPS) - Basic (USD)

Earnings Per Share (EPS) - Diluted (USD)

a100c3a579ddf25f290c2113e291bc0d46b1b0d798260978fc3599d30aa8abb7

Current Assets (USD, thousands)

Cash and Cash Equivalents (USD, thousands)

Accounts Receivable (USD, thousands)

Inventory (USD, thousands)

Non-Current Assets (USD, thousands)

Property, Plant, and Equipment (PP&E) (USD, thousands)

Goodwill (USD, thousands)

Intangible Assets (USD, thousands)

Current Liabilities (USD, thousands)

Accounts Payable (USD, thousands)

Short-term Debt (USD, thousands)

Accrued Expenses (USD, thousands)

Non-Current Liabilities (USD, thousands)

Long-term Debt (USD, thousands)

Lease Liabilities (USD, thousands)

Deferred Tax Liabilities (USD, thousands)

Shareholders' Equity (USD, thousands)

Retained Earnings (USD, thousands)

Common Stock (USD, thousands)

Additional Paid-in Capital (USD, thousands)

472ca0d55a9ddfd14782eec888ba04d5ef4de3abde86596e304947b9057b98cb

0751846166ba9870a3d92e5b861e9e8d43012d461b383c86ca09307dce09dba8

Product sales (USD, thousands)

Royalties and license fees (USD, thousands)

Research, development and other (USD, thousands)

Total revenue (USD, thousands)

Product costs (USD, thousands)

Research and development (USD, thousands)

Selling, general and administrative (USD, thousands)

Acquired intangible asset amortization (USD, thousands)

Restructuring expense (USD, thousands)

Contingent consideration (gain) expense (USD, thousands)

Total operating costs and expenses (USD, thousands)

Operating (loss) income (USD, thousands)

Interest expense, net (USD, thousands)

Foreign exchange gain (loss) (USD, thousands)

Investment income, net (USD, thousands)

Other expense, net (USD, thousands)

(Loss) income before income taxes (USD, thousands)

Income tax benefit (expense) (USD, thousands)

Net (loss) income (USD, thousands)

Basic net (loss) income per share (USD)

Diluted net (loss) income per share (USD)

6d46747d21306de1a7182f0cd6a5f067e0f0878a27c842abc236d9d76199d8fd

Cash and cash equivalents (USD, thousands)

Available-for-sale securities (USD, thousands)

Accounts receivable, net (USD, thousands)

Contract assets, current (USD, thousands)

Inventories (USD, thousands)

Income tax receivable, current (USD, thousands)

Prepaids and other, current (USD, thousands)

Total Current Assets (USD, thousands)

Property and equipment, net (USD, thousands)

Intangible assets, net (USD, thousands)

Other assets, noncurrent (USD, thousands)

Total Assets (USD, thousands)

Accounts payable (USD, thousands)

Accrued liabilities - Compensation (USD, thousands)

Accrued liabilities - Accrued other (USD, thousands)

Deferred revenue, current (USD, thousands)

Income tax payable, current (USD, thousands)

Total Current Liabilities (USD, thousands)

Long-term debt, net (USD, thousands)

Deferred revenue, less current portion (USD, thousands)

Deferred income taxes, noncurrent (USD, thousands)

Other long-term liabilities (USD, thousands)

Total Liabilities (USD, thousands)

Series A Preferred stock (USD, thousands)

Common stock (USD, thousands)

Additional paid-in capital (USD, thousands)

Accumulated other comprehensive loss (USD, thousands)

Retained earnings (USD, thousands)

Total Stockholders’ Equity (USD, thousands)

Total Liabilities and Stockholders’ Equity (USD, thousands)

bf3eae1d85dbd3a2e8125f2c98538a885ae66f43620287b0b84dbc990b4751b4

Surmodics Inc (SRDX)

Financials